On January 14, 2021, the Federal Court issued a decision
(Janssen Inc. et al v. Apotex Inc. et al, 2021 FC 7) in
the consolidated infringement action brought under s. 6(1) of the
Patented Medicine (Notice of Compliance) (PM(NOC))
Regulations by Janssen against Apotex, Dr. Reddy's
Laboratory, and Pharmascience. In this decision, the Court
invalidated the asserted claims of Janssen's Canadian Patent
2,661,422 (the 422 Patent), which claimed the combined use of the
two active ingredients found in Janssen's brand name drug
ZYTIGA, abiraterone acetate and prednisone, in the treatment of
prostate cancer. Concurrently, the Court dealt with Apotex'
counterclaim under s. 6(3) of the PM(NOC) Regulations to
invalidate the asserted and non-asserted claims of the 422 Patent.
This decision provides important lessons and reminders in drafting
and prosecuting patent applications relating to use of therapeutic
agents in the treatment of diseases.